Abstracts tagged "Enthesis and juvenile idiopathic arthritis (JIA)"

Abstract Number: 46 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Kristina Unnebrink⁴ and Jaclyn K. Anderson⁵, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…
Abstract Number: 45 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Clinic, Sankt Augustin, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 1477 • 2015 ACR/ARHP Annual Meeting
Patterns of Enthesitis and Arthritis in Juvenile Idiopathic Arthritis
Florence A. Aeschlimann¹, Mira van Veenendaal¹, Simon Eng² and Rae S.M. Yeung¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²151 Beecroft Rd., Apt. 604, University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses a heterogeneous group of diseases characterized by chronic joint inflammation with presence of enthesitis as an important classification criteria.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].